What should I pay attention to when using atezolizumab/Tecentriq?

Atezolizumab (TECENTRIQ) is a programmed death ligand 1 (PD-L1) blocking antibody used to treat patients with a variety of cancers. Its side effects also vary from disease to disease, as follows:

The most common adverse reactions (≥20%) of atezolizumab (TECENTRIQ) as a single drug are fatigue/asthenia, nausea, cough, dyspnea and decreased appetite.

The most common adverse reactions (≥20%) when used in combination with other antineoplastic drugs in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are fatigue/asthenia, nausea, alopecia, constipation, diarrhea and decreased appetite.

The most common adverse reactions (≥20%) in patients with liver cancer treated with atezolizumab (TECENTRIQ) combined with bevacizumab include hypertension, fatigue and proteinuria.

The most common adverse reactions (≥20%) of atezolizumab (TECENTRIQ) combined with cobimetinib and vemurafenib in the treatment of melanoma patients are rash, musculoskeletal pain, fatigue, hepatotoxicity, pyrexia, nausea, pruritus, edema, stomatitis, hypothyroidism, and photosensitivity reaction).

Reference: Atezolizumab (TECENTRIQ) Instructions for Use